Insulet Corporation (PODD) Stock Analysis
Healthcare · Medical Devices
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes... Read more
TrendMatrix rates Insulet Corporation (PODD) as Hold with moderate confidence. The stock trades at $215.13 with +39.1% upside to the $300.44 price target. Overall score: 5.8/10 across 10 analysis dimensions. Reward/risk ratio: 11.8:1.
Passes 3/5 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates Insulet Corporation (PODD) as Hold with moderate confidence. Score 5.8/10.
Take-profit target: $300.44 (+39.1% upside). Reward/risk ratio: 11.8:1. Stop-loss: $208.80.
Negative momentum; Below 200-day MA.
Insulet Corporation trades at a P/E of 65.2 (forward 28.0). TrendMatrix value score: 4.7/10. Verdict: Hold.
34 analysts cover PODD with a consensus score of 4.3/5. Average price target: $353.
What does Insulet Corporation do?Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent...
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.